Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Abstract
Background
Quantitative fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers are associated with prognosis following stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC); however, their relationship with patterns of failure remains poorly defined. We evaluated the prognostic significance of pretreatment metabolic PET parameters following definitive SBRT. PATIENTS AND
Methods
Patients with T1-3N0M0 ES-NSCLC treated with SBRT between January 2010 and December 2024 were identified from a prospectively maintained institutional database. Pretreatment FDG-PET metrics including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were stratified into low-, intermediate-, and high-risk groups. Overall survival (OS); cancer-specific survival; and local, regional, and distant failure were analyzed using competing-risk methods and multivariable Fine-Gray regression.
Results
A total of 168 patients were included (median age, 77 years; median follow-up, 34.6 months). Local, regional, and distant failure occurred in 3.6%, 10.1%, and 15.5% of patients, respectively. Increasing TLG, SUVmax, SUVmean, and MTV were associated with inferior OS on univariable analysis, while high-risk TLG (HR, 2.26; P = .014) and SUVmean (HR, 2.72; P = .008) remained independent predictors of worse OS. No PET biomarker predicted local failure. Conversely, high-risk TLG and MTV independently predicted regional recurrence, while high-risk TLG, SUVmax, and SUVmean independently predicted distant metastasis.
Conclusion
Pretreatment FDG-PET metabolic biomarkers identify patients at increased risk of regional and distant recurrence following SBRT for ES-NSCLC but do not predict local failure after modern ablative radiotherapy. TLG demonstrated the most consistent prognostic performance and may represent a clinically useful biomarker for risk-adapted staging, surveillance, and future treatment intensification strategies.